How to buy Nabriva Therapeutics stock - 07 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Nabriva Therapeutics stock

Own Nabriva Therapeutics stock in just a few minutes.

Fact checked

Nabriva Therapeutics plc is a biotechnology business based in the US. Nabriva Therapeutics shares (NBRV) are listed on the NASDAQ and all prices are listed in US Dollars. Nabriva Therapeutics employs 162 staff and has a trailing 12-month revenue of around USD$2.9 million.

How to buy shares in Nabriva Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Nabriva Therapeutics. Find the stock by name or ticker symbol: NBRV. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Nabriva Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Nabriva Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Nabriva Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Nabriva Therapeutics share price

Use our graph to track the performance of NBRV stocks over time.

Nabriva Therapeutics shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$1.84 - USD$15.441
50-day moving average USD$2.8818
200-day moving average USD$4.2687
Wall St. target priceUSD$9
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.881

Buy Nabriva Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Nabriva Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nabriva Therapeutics financials

Revenue TTM USD$2.9 million
Gross profit TTM USD$-17,004,000
Return on assets TTM -59.51%
Return on equity TTM -198.02%
Profit margin 0%
Book value $2.415
Market capitalisation USD$40.7 million

TTM: trailing 12 months

Shorting Nabriva Therapeutics shares

There are currently 1.3 million Nabriva Therapeutics shares held short by investors – that's known as Nabriva Therapeutics's "short interest". This figure is 75.5% up from 728,638 last month.

There are a few different ways that this level of interest in shorting Nabriva Therapeutics shares can be evaluated.

Nabriva Therapeutics's "short interest ratio" (SIR)

Nabriva Therapeutics's "short interest ratio" (SIR) is the quantity of Nabriva Therapeutics shares currently shorted divided by the average quantity of Nabriva Therapeutics shares traded daily (recently around 1.1 million). Nabriva Therapeutics's SIR currently stands at 1.17. In other words for every 100,000 Nabriva Therapeutics shares traded daily on the market, roughly 1170 shares are currently held short.

However Nabriva Therapeutics's short interest can also be evaluated against the total number of Nabriva Therapeutics shares, or, against the total number of tradable Nabriva Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nabriva Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Nabriva Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0609% of the tradable shares (for every 100,000 tradable Nabriva Therapeutics shares, roughly 61 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Nabriva Therapeutics.

Find out more about how you can short Nabriva Therapeutics stock.

Nabriva Therapeutics share dividends

We're not expecting Nabriva Therapeutics to pay a dividend over the next 12 months.

Have Nabriva Therapeutics's shares ever split?

Nabriva Therapeutics's shares were split on a 1:10 basis on 3 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nabriva Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Nabriva Therapeutics shares which in turn could have impacted Nabriva Therapeutics's share price.

Nabriva Therapeutics share price volatility

Over the last 12 months, Nabriva Therapeutics's shares have ranged in value from as little as $1.84 up to $15.441. A popular way to gauge a stock's volatility is its "beta".

NBRV.US volatility(beta: 1.91)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nabriva Therapeutics's is 1.9077. This would suggest that Nabriva Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Nabriva Therapeutics overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site